223 related articles for article (PubMed ID: 36116682)
1. Therapeutics targeting the metastatic breast cancer bone microenvironment.
Ihle CL; Wright-Hobart SJ; Owens P
Pharmacol Ther; 2022 Nov; 239():108280. PubMed ID: 36116682
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
Wood R; Mitra D; de Courcy J; Iyer S
Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
[TBL] [Abstract][Full Text] [Related]
3. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
4. Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma.
Harvey HA
Cancer; 1997 Oct; 80(8 Suppl):1646-51. PubMed ID: 9362431
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs mediated interaction of tumor microenvironment cells with breast cancer cells during bone metastasis.
Akshaya RL; Saranya I; Selvamurugan N
Breast Cancer; 2023 Nov; 30(6):910-925. PubMed ID: 37578597
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer.
Futakuchi M; Fukamachi K; Suzui M
Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):206-211. PubMed ID: 26656603
[TBL] [Abstract][Full Text] [Related]
7. Targeting Metabolic Adaptations in the Breast Cancer-Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy.
Zuo Q; Mogol AN; Liu YJ; Santaliz Casiano A; Chien C; Drnevich J; Imir OB; Kulkoyluoglu-Cotul E; Park NH; Shapiro DJ; Park BH; Ziegler Y; Katzenellenbogen BS; Aranda E; O'Neill JD; Raghavendra AS; Tripathy D; Madak Erdogan Z
Mol Cancer Res; 2022 Jun; 20(6):923-937. PubMed ID: 35259269
[TBL] [Abstract][Full Text] [Related]
8. The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities.
Mehraj U; Ganai RA; Macha MA; Hamid A; Zargar MA; Bhat AA; Nasser MW; Haris M; Batra SK; Alshehri B; Al-Baradie RS; Mir MA; Wani NA
Cell Oncol (Dordr); 2021 Dec; 44(6):1209-1229. PubMed ID: 34528143
[TBL] [Abstract][Full Text] [Related]
9. Insights into immuno-oncology drug development landscape with focus on bone metastasis.
Kähkönen TE; Halleen JM; MacRitchie G; Andersson RM; Bernoulli J
Front Immunol; 2023; 14():1121878. PubMed ID: 37475868
[TBL] [Abstract][Full Text] [Related]
10. Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases.
Hiraga T
Expert Opin Investig Drugs; 2016; 25(3):319-34. PubMed ID: 26778342
[TBL] [Abstract][Full Text] [Related]
11. Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer.
Klar N; Rosenzweig M; Diergaarde B; Brufsky A
Clin Breast Cancer; 2019 Aug; 19(4):304-310. PubMed ID: 30827763
[TBL] [Abstract][Full Text] [Related]
12. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
13. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer.
Lin NU; Thomssen C; Cardoso F; Cameron D; Cufer T; Fallowfield L; Francis PA; Kyriakides S; Pagani O; Senkus E; Costa A; Winer EP;
Breast; 2013 Jun; 22(3):203-10. PubMed ID: 23601761
[TBL] [Abstract][Full Text] [Related]
14. The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets.
Yang G; Lu T; Weisenberger DJ; Liang G
Genes (Basel); 2022 Aug; 13(9):. PubMed ID: 36140723
[TBL] [Abstract][Full Text] [Related]
15. Integrating the immune microenvironment of prostate cancer induced bone disease.
Ihle CL; Owens P
Mol Carcinog; 2020 Jul; 59(7):822-829. PubMed ID: 32233011
[TBL] [Abstract][Full Text] [Related]
16. Antrodia cinnamomea is a potentially effective complementary medicine for adjuvant therapy against breast cancer with bone metastasis: A case report.
Long H; Hu CT; Prijatelj V; Weng CF
Medicine (Baltimore); 2020 Jul; 99(27):e20808. PubMed ID: 32629666
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
[TBL] [Abstract][Full Text] [Related]
18. Unique macrophage phenotypes activated by BMP signaling in breast cancer bone metastases.
Ihle CL; Straign DM; Canari JA; Torkko KC; Zolman KL; Smith EE; Owens P
JCI Insight; 2024 Jan; 9(1):. PubMed ID: 38193534
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer Bone Metastasis: A Narrative Review of Emerging Targeted Drug Delivery Systems.
Shao H; Varamini P
Cells; 2022 Jan; 11(3):. PubMed ID: 35159207
[TBL] [Abstract][Full Text] [Related]
20. Different Targeting Strategies for Treating Breast Cancer Bone Metastases.
Irshad I; Varamini P
Curr Pharm Des; 2018; 24(28):3320-3331. PubMed ID: 29921200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
